Which medications in the drug class MAO-B inhibitors are used in the treatment of Parkinson Disease?

Updated: Aug 29, 2019
  • Author: Robert A Hauser, MD, MBA; Chief Editor: Selim R Benbadis, MD  more...
  • Print

MAO-B inhibitors

MAO-B inhibitors inhibit the activity of MAO-B oxidases that are responsible for inactivating dopamine.

Selegiline (Eldepryl, Zelapar)

Selegiline is approved as adjunctive therapy to levodopa/carbidopa in patients who exhibit deterioration in response to that therapy. For patients who are experiencing motor fluctuations on levodopa/carbidopa, the addition of selegiline reduces off time, improves motor function, and allows levodopa dose reductions. If a patient experiences an increase in troublesome dyskinesia, reduce the levodopa dose. Selegiline blocks the breakdown of dopamine and extends the duration of action of each dose of levodopa.

Rasagiline (Azilect)

Rasagiline is indicated for the treatment of the signs and symptoms of idiopathic PD as initial monotherapy and as adjunctive therapy to levodopa. Rasagiline is an irreversible MAO-B inhibitor that blocks dopamine degradation. Rasagiline at a dosage of 1 mg once daily is given as monotherapy. When it is given as adjunctive therapy, an initial dose of 0.5 mg once daily is administered. Dosage adjustments are required if clinical response is not seen.

Safinamide (Xadago)

Safinamide inhibits MAO-B activity, by blocking the catabolism of dopamine. It is indicated as add-on treatment for patients with Parkinson disease who are currently taking levodopa/carbidopa and experiencing “off” episodes.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!